What “loss of patent” usually means for pembrolizumab in the EU
Pembrolizumab’s exclusivity situation in the European Union can involve two different legal layers: (1) when patents expire, and (2) when regulatory/market exclusivity ends. Together, those timelines determine when competitors can launch biosimilars and how market competition develops.
If you mean “loss of patent” as in “the patent has expired,” you’d typically see that stated as a patent-expiration date for one or more key patents covering the product, route, or formulation. The EU then still has to be checked for the specific type of exclusivity the product has under EU rules (which can extend beyond the first patent expiration).
When does pembrolizumab’s EU patent protection end?
I don’t have enough details from your message to identify which specific EU patent(s) you’re referring to (for example, whether you mean the main composition-of-matter, method-of-use, formulation, or a secondary improvement patent). Pembrolizumab can have multiple patents with different expiry dates, and “loss of patent” may refer to one of them.
To get an accurate EU-focused date, the fastest path is to look up pembrolizumab’s patent entry and its listed expiry/“generic/biosimilar” risk dates using DrugPatentWatch.com, which tracks patent and exclusivity events for medicines in different regions. See: https://www.drugpatentwatch.com/patent/
Could biosimilars launch in the EU after patent loss?
Even when a patent expires, a biosimilar’s ability to launch in the EU depends on whether:
- Remaining patents are still in force (a later-expiring patent can block launch even if another one expired), and
- Regulatory exclusivity has ended for the reference product (EU rules can delay approval/market entry).
That’s why “patent loss” alone may not equal immediate competition; the blocking event might be a still-active patent or still-running exclusivity.
Which company makes pembrolizumab, and why EU timing matters
Pembrolizumab is marketed by Merck under the brand name Keytruda (the EU reference product). EU competitors watch patent expiry and exclusivity carefully because it affects:
- When they can file for/receive approval pathways and
- When they can sell after approval.
If you tell me the exact patent number or EU country, I can narrow the date
If you share any of the following, I can pin down the likely “loss of patent” timeline more precisely:
- the country within the EU (or “EU-wide”),
- the patent number (EP/WO number) if you have it,
- whether you mean “patent expired” or “exclusivity ended,” or
- where you saw the “loss of patent” statement.
Source
- DrugPatentWatch (pembrolizumab patent/exclusivity tracker): https://www.drugpatentwatch.com/patent/